» Articles » PMID: 31092022

Defining Clinically Important Difference in the Atrial Fibrillation Effect on Quality-of-Life Score

Abstract

Background The Atrial Fibrillation Effect on Quality-of-Life (AFEQT) questionnaire has recently been validated to measure the impact of atrial fibrillation on quality of life, but a clinically important difference in AFEQT score has not been well defined. Methods and Results To determine the clinically important difference in overall AFEQT (score range= 0 [worst] to 100 [best]) and selected subscales, we analyzed data in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry, a United States-based outpatient atrial fibrillation registry. AFEQT was assessed at baseline and 1 year in a subset of 1347 ORBIT-AF patients from 80 US sites participating in ORBIT-AF from June 2010 to August 2011. The mean change method was used to relate changes in 1-year AFEQT scores to clinically important changes in the physician assessment of European Heart Rhythm Association functional status (1 class improvement and separately 1 class deterioration). Clinically important differences and 95% CI corresponding to either a 1 European Heart Rhythm Association class improvement or deterioration were 5.4 (3.6-7.2) and -4.2 (-6.9 to -1.5) AFEQT points, respectively. Similarly, clinically important difference values were seen for a 1 European Heart Rhythm Association class improvement for the AFEQT subscales Activities of Daily Living and Symptoms: 5.1 (2.5-7.6) and 7.1 (5.3-9.0) AFEQT points, respectively. Conclusions Based on the anchor of 1 European Heart Rhythm Association class change, changes in AFEQT score of + or -5 points are clinically important changes in patients' health. Clinical Trial Registration URL: https://clinicaltrials.gov . Unique identifier: NCT01165710.

Citing Articles

Identifying potential action points for reducing kinesiophobia among atrial fibrillation patients: a network and DAG analysis.

Chen L, Gou X, Yang S, Dong H, Dong F, Wu J Qual Life Res. 2025; .

PMID: 39928211 DOI: 10.1007/s11136-025-03897-z.


Multielectrode Radiofrequency Balloon Catheter for Paroxysmal Atrial Fibrillation: Results From the Global, Multicenter, STELLAR Study.

Goyal S, Pappone C, Grimaldi M, Lee S, Mountantonakis S, DeVille J J Cardiovasc Electrophysiol. 2024; 36(2):376-386.

PMID: 39686569 PMC: 11837878. DOI: 10.1111/jce.16524.


Safety, efficacy, and quality of life outcomes of pulsed field ablation in Japanese patients with atrial fibrillation: results from the PULSED AF trial.

Yamane T, Sasano T, Tomita H, Aoyama D, Miyazaki S, Takigawa M J Interv Card Electrophysiol. 2024; 68(1):149-157.

PMID: 39243306 PMC: 11832727. DOI: 10.1007/s10840-024-01912-w.


Pulmonary Vein Isolation vs Sham Intervention in Symptomatic Atrial Fibrillation: The SHAM-PVI Randomized Clinical Trial.

Dulai R, Sulke N, Freemantle N, Lambiase P, Farwell D, Srinivasan N JAMA. 2024; .

PMID: 39221629 PMC: 11369784. DOI: 10.1001/jama.2024.17921.


Quality of life improvement from thoracoscopic atrial fibrillation ablation in women versus men: a prospective cohort study.

Vos L, Vos R, Nieuwkerk P, Vos P, Hofman F, Klautz R Interdiscip Cardiovasc Thorac Surg. 2024; 39(1).

PMID: 38991842 PMC: 11268440. DOI: 10.1093/icvts/ivae132.